Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Koh Nakamaru

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6116-9358; OpenAlex author ID A5077110871. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 3 papers

Papers 8

  1. Fecal Bifidobacterium Serves as a Predictor of Postoperative Recurrence After Neoadjuvant Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1016/j.gastha.2025.100779↗
  2. Distinct difference of pancreatic tissue-specific microbiome in autoimmune pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-026-44821-w↗
  3. Multi-hole Versus Fully Covered Self-expandable Metal Stents for Distal Biliary Obstruction in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002722↗
  4. Impact of endoscopic ultrasound-guided tissue acquisition on prognosis and peritoneal lavage cytology in resectable or borderline resectable pancreatic ductal … Co-author DOI 10.1016/j.pan.2024.06.001↗
  5. Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.04.001↗
  6. A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer. Co-author DOI 10.3390/jcm12103477↗
  7. Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Co-author DOI 10.3390/cancers14051354↗
  8. Usefulness of half-covered metallic stent placement in preventing acute cholecystitis complication in pancreatic cancer-induced distal biliary stricture. Co-author DOI 10.1002/jgh3.12409↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tsukasa Ikeura · 8 shared papers, 2020–2026 · strength 1.49
  2. Makoto Naganuma · 7 shared papers, 2020–2026 · strength 1.36
  3. Sohei Satoi · 6 shared papers, 2022–2026 · strength 1.11
  4. Daisuke Hashimoto · 6 shared papers, 2022–2026 · strength 1.11
  5. Takashi Ito · 6 shared papers, 2020–2026 · strength 1.08
  6. So Yamaki · 5 shared papers, 2022–2026 · strength 0.82
  7. Ayaka Takaori · 3 shared papers, 2023–2026 · strength 0.54
  8. Masashi Kanai · 2 shared papers, 2026 · strength 0.52
  9. Tomohisa Yamamoto · 3 shared papers, 2022–2023 · strength 0.42
  10. Motonobu Maruo · 2 shared papers, 2024–2026 · strength 0.40
  11. Hidetaka Miyazaki · 2 shared papers, 2024–2026 · strength 0.40
  12. Mitsugu Sekimoto · 2 shared papers, 2022–2023 · strength 0.27
  13. Makoto Takaoka · 2 shared papers, 2020–2024 · strength 0.27
  14. Toshihiko Matsumoto · 1 shared paper, 2023 · strength 0.15
  15. Tatsuki Ikoma · 1 shared paper, 2023 · strength 0.15
  16. Takayasu Kurata · 1 shared paper, 2023 · strength 0.15
  17. Satoshi Hirooka · 1 shared paper, 2022 · strength 0.13
  18. Yuki Matsui · 1 shared paper, 2022 · strength 0.13
  19. Hideaki Miyoshi · 1 shared paper, 2020 · strength 0.11
  20. Kazuichi Okazaki · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.